Safety and Effectiveness of Eye90 Microspheres™ in the Treatment of Unresectable Hepatocellular Carcinoma (HCC) and Metastatic Colorectal Cancer (mCRC)

Inclusion Criteria:

* Measurable disease defined as at least one unidimensional measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI).
* Must have at least one lesion \> 2 cm within the target perfused volume.
* At least one lesion must meet the definition of target lesion as defined by RECIST 1.1 or mRECIST.
* Total linear length of all lesions must be ≤ 9 cm.
* Must have preservation of \>700cc of normal liver parenchyma outside of treated volume.
* Hypervascular lesions on CT scan with 99mTC MAA SPECT/CT T:N ratio 3:1 or higher and Hypervascular on CBCT.
* No prior locoregional therapies in the liver other than previous Drug Eluting Bead TACE and/or local HCC recurrence after thermal ablation. Last TACE and/or ablation treatment must be at least 3 months prior to informed consent. Prior Lumi or Lipiodol TACE is not allowed.
* Life expectancy of ≥ 6 months.
* ≥ 18 years old.

Exclusion Criteria:

* Hemoglobin ≤ 85 mg/L.
* Platelet count \< 50,000/microliter or prothrombin (PT) activity \> 50% normal
* INR \> 1.4 (if anticoagulated, reversal must be achieved prior to any angiographic procedures).
* ALT \> 2.5x upper limit
* AST \> 2.5x upper limit
* For HCC subjects, Bilirubin ≥ 2 mg/dL.
* For mCRC subjects, Bilirubin ≥ 1.2 mg/dL.
* eGFR ≤ 60 mL/min/1.73 m2.
* Portal vein thrombosis (PVT).
* Incompetent biliary duct system, prior biliary intervention, or a compromised Ampulla of Vater
* Estimated lung dose \> 30 Gy as calculated using the lung shunt % and partition model.